Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers

Author/s: 
Biglione, B., Gitin, A., Gorelick, P., Hennekens, C.
Date Added: 
November 11, 2019
Journal/Publication: 
The American Journal of Medicine
Publication Date: 
October 12, 2019
Type: 
Meta-analyses, Reviews, and Guidelines
Format: 
Article
DOI (1): 
https://doi.org/10.1016/j.amjmed.2019.10.023

RPR Commentary

While the full article is not available for free, I though the abstract might be of interest and value.  James W. Mold, MD, MPH

Abstract

Migraine headaches are among the most common and potentially debilitating disorders encountered by primary healthcare providers. In the treatment of acute migraine as well as prevention of recurrent attacks there are prescription drugs of proven benefit. For those without health insurance or high co-pays, however, they may be neither available nor affordable and, for all patients, they may be either poorly tolerated or contraindicated.

The totality of evidence, which includes data from randomized trials, suggests that high-dose aspirin, in doses from 900 to 1300 milligrams, taken at the onset of symptoms, is an effective and safe treatment option for acute migraine headaches. In addition, the totality of evidence, including some, but not all, randomized trials, suggests the possibility that daily aspirin in doses from 81 to 325 milligrams, may be an effective and safe treatment option for the prevention of recurrent migraine headaches.

The relatively favorable side effect profile of aspirin and extremely low costs compared with other prescription drug therapies may provide additional options for primary healthcare providers treating acute as well as recurrent migraine headaches.

Text Availability

Commercial full text (fees may apply)